Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.

Thomas A, Virdee PS, Eatock M, Lord SR, Falk S, Anthoney DA, Turkington RC, Goff M, Elhussein L, Collins L, Love S, Moschandreas J, Middleton MR.

Eur J Cancer. 2020 Jan;124:131-141. doi: 10.1016/j.ejca.2019.10.010. Epub 2019 Nov 22.

2.

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.

Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Gut. 2019 Nov;68(11):1918-1927. doi: 10.1136/gutjnl-2018-317624. Epub 2019 Mar 9.

3.

Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.

Ishak KJ, Rael M, Hicks M, Mittal S, Eatock M, Valle JW.

J Comp Eff Res. 2018 Oct;7(10):947-958. doi: 10.2217/cer-2018-0020. Epub 2018 Aug 31.

PMID:
30168349
4.

Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma.

Blayney JK, Cairns L, Li G, McCabe N, Stevenson L, Peters CJ, Reid NB, Spence VJ, Chisambo C, McManus D, James J, McQuaid S, Craig S, Arthur K, McArt D, Ong CJ, Lao-Sirieix P, Hamilton P, Salto-Tellez M, Eatock M, Coleman HG, Fitzgerald RC, Kennedy RD, Turkington RC; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.

Oncotarget. 2018 Apr 6;9(26):18518-18528. doi: 10.18632/oncotarget.24906. eCollection 2018 Apr 6.

5.

Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

Propper D, Jones K, Anthoney DA, Mansoor W, Ford D, Eatock M, Agarwal R, Inatani M, Saito T, Abe M, Evans TR.

BMC Cancer. 2016 Oct 10;16(1):779.

6.

Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy.

Ardill JE, Johnston BT, McCance DR, Eatock M.

Ann Clin Biochem. 2017 Mar;54(2):297-301. doi: 10.1177/0004563216672492. Epub 2016 Nov 14.

PMID:
27638929
7.

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.

Graham JS, Boyd K, Coxon FY, Wall LR, Eatock MM, Maughan TS, Highley M, Soulis E, Harden S, Bützberger-Zimmerli P, Evans TR.

BMC Res Notes. 2016 Mar 12;9:161. doi: 10.1186/s13104-015-1778-4.

8.

Clinical tumor staging of adenocarcinoma of the esophagus and esophagogastric junction.

Turkington RC, Parkes E, Kennedy RD, Eatock MM, Harrison C, McCloskey P, Purcell C.

J Clin Oncol. 2015 Mar 20;33(9):1088. doi: 10.1200/JCO.2014.59.2402. Epub 2015 Feb 2. No abstract available.

PMID:
25646194
9.

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt D, Rawcliffe C, Nanson G, Neoptolemos J.

Lancet Oncol. 2014 Jul;15(8):829-40. doi: 10.1016/S1470-2045(14)70236-0. Epub 2014 Jun 19.

PMID:
24954781
10.

Use of sorafenib in a corticotropin-secreting pancreatic neuroendocrine carcinoma.

Graham U, Eatock M, Atkinson B.

Pancreas. 2014 Jul;43(5):809-10. doi: 10.1097/MPA.0000000000000144. No abstract available.

PMID:
24921203
11.

A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours.

Valle JW, Eatock M, Clueit B, Gabriel Z, Ferdinand R, Mitchell S.

Cancer Treat Rev. 2014 Apr;40(3):376-89. doi: 10.1016/j.ctrv.2013.08.007. Epub 2013 Sep 8. Review. Erratum in: Cancer Treat Rev. 2014 Sep;40(8):1037.

12.

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.

Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, Valle J, Smith D, Wadsley J, Cunningham D, Pandha H, Neoptolemos JP, Middleton G.

Cancer Immunol Immunother. 2014 Feb;63(2):175-83. doi: 10.1007/s00262-013-1502-y. Epub 2013 Nov 29.

PMID:
24292263
13.

A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.

Turkington RC, Purcell C, James CR, Millar J, Napier E, Law D, Gallagher R, Morris M, Wilson RH, Eatock MM.

Invest New Drugs. 2014 Apr;32(2):250-60. doi: 10.1007/s10637-013-9970-7. Epub 2013 May 11.

PMID:
23665866
14.

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.

Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Valladares-Ayerbes M, Swieboda-Sadlej A, Van Cutsem E, Nanayakkara N, Sun YN, Zhong ZD, Bass MB, Adewoye AH, Bodoky G.

Ann Oncol. 2013 Mar;24(3):710-8. doi: 10.1093/annonc/mds502. Epub 2012 Oct 28.

15.

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.

Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, Matsumura Y, Kataoka K, Nishiya T.

Br J Cancer. 2011 Feb 15;104(4):593-8. doi: 10.1038/bjc.2011.6. Epub 2011 Feb 1.

16.

A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.

Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I.

Clin Cancer Res. 2011 Mar 15;17(6):1561-70. doi: 10.1158/1078-0432.CCR-10-1927. Epub 2011 Jan 28. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5488.

17.

Attitudes towards weight and weight assessment in oncology patients: survey of hospice staff and patients with advanced cancer.

Watson M, Coulter S, McLoughlin C, Kelt S, Wilkinson P, McPherson A, Wilson R, Eatock M.

Palliat Med. 2010 Sep;24(6):623-9. doi: 10.1177/0269216310373163. Epub 2010 Jul 21.

PMID:
20659976
18.

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP.

J Clin Oncol. 2009 Nov 20;27(33):5513-8. doi: 10.1200/JCO.2009.24.2446. Epub 2009 Oct 26.

PMID:
19858379
19.

Predictive and prognostic markers in colorectal cancer.

Turkington RC, Coyle VM, Johnston PG, Eatock MM.

Per Med. 2007 Aug;4(3):295-306. doi: 10.2217/17410541.4.3.295.

PMID:
29788671
20.

Cholethorax following percutaneous transhepatic biliary drainage.

Turkington RC, Leggett JJ, Hurwitz J, Eatock MM.

Ulster Med J. 2007 May;76(2):112-3. No abstract available.

21.

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.

Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, Wilke H, Evans TR.

Cancer Chemother Pharmacol. 2008 Mar;61(3):435-41. Epub 2007 Apr 18.

PMID:
17440725
22.

Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J.

Br J Cancer. 2006 Aug 21;95(4):450-6. Epub 2006 Aug 1.

23.

Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer.

Millar J, Scullin P, Morrison A, McClory B, Wall L, Cameron D, Philips H, Price A, Dunlop D, Eatock M.

Br J Cancer. 2005 Nov 14;93(10):1112-6.

24.

Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors.

Lapointe R, Létourneau R, Steward W, Hawkins RE, Batist G, Vincent M, Whittom R, Eatock M, Jolivet J, Moore M.

Ann Oncol. 2005 Feb;16(2):289-93.

PMID:
15668286
25.

A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.

Eatock M, Cassidy J, Johnson J, Morrison R, Devlin M, Blackey R, Owen S, Choi L, Twelves C.

Cancer Chemother Pharmacol. 2005 Jan;55(1):39-46. Epub 2004 Sep 10.

PMID:
15368080
26.

The medical management of pancreatic cancer: a review.

McKenna S, Eatock M.

Oncologist. 2003;8(2):149-60. Review.

27.

Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.

Díaz-Rubio E, Evans TR, Tabemero J, Cassidy J, Sastre J, Eatock M, Bisset D, Regueiro P, Baselga J.

Ann Oncol. 2002 Apr;13(4):558-65.

PMID:
12056706
28.
29.

Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver.

Sharma RA, Eatock MM, Twelves CJ, Brown G, McLelland HR, Clayton KT, O'Byrne KJ, Moyses C, Carmichael J, Steward WP.

Cancer Chemother Pharmacol. 2001 Sep;48(3):197-201.

PMID:
11592340
30.

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.

Eatock MM, Anthony DA, El-Abassi M, Wilson P, Paul J, Smith M, Soukop M, Evans TR.

Br J Cancer. 2000 Jun;82(12):1925-31.

31.

Tumour vasculature as a target for anticancer therapy.

Eatock MM, Schätzlein A, Kaye SB.

Cancer Treat Rev. 2000 Jun;26(3):191-204. Review.

PMID:
10814561
32.

Activity of doxorubicin covalently bound to a novel human serum albumin microcapsule.

Eatock M, Church N, Harris R, Angerson W, McArdle C, French R, Twelves C.

Invest New Drugs. 1999;17(2):111-20.

PMID:
10638482
33.

Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group.

Dunlop DJ, Eatock MM, Paul J, Anderson S, Reed NS, Soukop M, Lucie N, Fitzsimmons EJ, Tansey P, Steward WP.

Clin Oncol (R Coll Radiol). 1998;10(2):107-14.

PMID:
9610900
34.

Bioavailability of subcutaneous 5-fluorouracil: a case report.

Eatock MM, Carlin W, Dunlop DJ, Soukop M, Watson DG.

Cancer Chemother Pharmacol. 1996;38(1):110-2.

PMID:
8603444

Supplemental Content

Loading ...
Support Center